<DOC>
	<DOCNO>NCT00073723</DOCNO>
	<brief_summary>The anticancer agent paclitaxel ( Taxol Injection Concentrate , Bristol-Meyers Squibb ) broad spectrum activity several human cancer include carcinoma ovary , breast , lung , esophagus head neck cancer . Taxol show remarkable activity metastatic breast cancer , yield response rate range 40 % 60 % chemotherapy-naive patient 25 % -30 % patient refractory anthracycline-containing regimen ( Taxol package insert ) . The major limitation Taxol poor water soluability require Cremophor ( contain castor oil ethanol ) solvent . Taxol vehicle must administer 3-24 hour , hypersensitivity reaction Cremophor require premedication routine corticosteroid , antihistamine , H2 antagonist .</brief_summary>
	<brief_title>Trial ABI-007 Administered Weekly Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>ABI-007 , unique protein formulation paclitaxel , develop reduce toxicity associate Taxol Cremophor EL/ethanol vehicle maintain improve chemotherapeutic effect drug . The activity ABI-007 malignancy yet well establish . This open-label Phase I/II study conduct define maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) ABI-007 , evaluate safety antitumor activity ABI-007 patient advance Stage IV non-small cell lung cancer ( NSCLC ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patients must : Histologically cytologically confirm advanced stage IV NSCLC evidence inoperable local recurrence metastasis If female , nonpregnant lactating , negative serum pregnancy test , either childbearing potential practicing approve contraception method Eighteen year age old No current active malignancy Measurable disease ( define RECIST criterion ) document radiographically Patient must receive prior chemotherapy treatment metastatic disease . Radiation therapy major bone marrowcontaining area must complete 3 week prior study entry . Prior treatment EGFtargeted therapy permit . If , baseline , patient ANC great equal 1.5 x 109 cells/L ; platelet great equal 100 x 109 cells/L Hgb great equal 9 g/dL If , baseline , patient AST ALT less equal 2.5 x upper limit normal range ; total bilirubin NORMAL ; creatinine level less equal 1.5 mg/dL alkaline phosphatase level less equal 2.5 x upper limit normal range ( unless alkaline phosphatase elevation felt related bone metastases radiologic evidence hepatic metastasis ) Expected survival great 12 week ECOG performance status 01 ( Karnofsky &gt; 70 ) Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Taxol</keyword>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
</DOC>